Showing 3711-3720 of 4066 results for "".
- Europe Grants DefenAge Skincare Master Patenthttps://practicaldermatology.com/news/europe-grants-defenage-skincare-master-patent/2460132/DefenAge Skincare now has a master patent from the European Patent Office that covers DefenAge’s core technology. The patent protects the exclusive rights of DefenAge to use the spectrum of immune peptides called defensins in topical cosmetic formulations in a specific range of co
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie
- PE-Backed Ownership of Dermatology Practices Is On The Risehttps://practicaldermatology.com/news/pe-backed-ownership-of-dermatology-practices-is-on-the-rise/2460104/Private equity firms have increased their financial stakes in dermatology practices throughout the United States, but exactly how this affects care is not fully understood yet. Private equity-backed dermatology management groups acquired 184 dermatology practices from 2012 to 2018, with
- Baylor Dermatologist Offers Anti-Aging Advice in Response to FaceApp Crazehttps://practicaldermatology.com/news/baylor-dermatologist-offers-anti-aging-advice-in-response-to-faceapp-craze/2460097/The FaceApp is taking social media by storm as celebrities and social media users across the nation morph their faces to look decades older. While it is currently being used for comedic purposes, you may have patients asking how to keep the app from turning into reality. Rajani Katta, M
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adu
- Skin Metabolomics: Estee Lauder Presents New Research at WCDhttps://practicaldermatology.com/news/skin-metabolomics-estee-lauder-presents-new-research-at-wcd/2460063/The Estée Lauder Companies Inc.Research & Development (R&D) team will present data focused on new findings in skin metabolomics, skin defense, ingredient science, and anti-aging research at the 2019 World Congress of Dermatology (WCD) in Milan, Italy from June 10 -15.